Immutep (ASX:IMM) clinical trial program milestones

0
70



Immutep Limited (ASX:IMM) CEO Marc Voigt talks about the company’s clinical trial program, key milestones, collaborations and potential for immunotherapy.

LEAVE A REPLY

Please enter your comment!
Please enter your name here